Press Kit

Technology Landos has identified Lanthionine Syn- thetase C-Like 2 (LANCL2) as a novel therapeutic target for autoimmune dis- eases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile. Landos’ lead asset, BT-11, is a novel small molecule targeting the Lanthio- nine Synthetase C-Like 2 (LANCL2) pathway in IBD. BT-11 intercepts IBD by decreasing the production of inflam- matory mediators and increasing anti- inflammatory molecules in the gastroin- testinal tract. Landos also has a robust pipeline of compounds for other autoimmune dis- eases.

Mission & Vision We believe in an accelerated path to cures. There is an unmet clinical need for safer, more effective therapeutics for au- toimmune diseases. Landos Biopharma, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in- class oral therapeutics for patients with autoimmune diseases. Our scientific foun- dation is anchored on informatics-enabled drug development with significant animal pharmacology data, safety, and mecha- nism of action (MoA) validation. Through focused execution, innovative proprietary technology with strong IP, and committed leadership with biopharma ex- perience, Landos is advancing its trans- formative lead IBD program into open in- vestigational new drug (IND) and clinical development in 2018.

Established in 2017 18 Employees 2 Patents (14 pending

internationally) $10M Series A

IBD Metrics 5,000,000 Worldwide 2,000,000 USA $100B Market 25% Growth 70-90% Require Surgery 100,000 Hospitalizations

IBD Market

Biologics

Immunomodulators

5'ASA

Others

Pre-IND Meeting - Jan 2016 Founded - Feb 2017 RBTC Innovator of the Year - July 2017 $10M Series A Financing - Sept 2017 2 IND Filings - May 2018 Phase 1 Clinical Studies - June 2018 Series B Financing - Q1 2019 Phase 2a Clinical Studies - Q2 2019 MILESTONES

FOUNDER Josep Bassaganya-Riera, DVM, PhD

Outlook Current therapies fail to induce remission and have significant side effects. Landos anticipates BT-11 will be safer than bio- logics, with easy and inexpensive produc- tion, low cost of goods, and potential for high margin. This will give Landos’ oral therapeutics unique properties and a dis- tinct market advantage.

www.landosbiopharma.com l 1800 Kraft Dr, Suite 216, Blacksburg, VA 24060 l 540.218.2232 l jbr@landosbiopharma.com